{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T08:14:41Z","timestamp":1783239281707,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,5]]},"DOI":"10.7759\/cureus.112071","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T07:18:47Z","timestamp":1783235927000},"source":"Crossref","is-referenced-by-count":0,"title":["Ten-Year Disease Control of Metastatic Pancreatic Neuroendocrine Tumour Treated With Everolimus"],"prefix":"10.7759","author":[{"given":"Madalena","family":"Machete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno M","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00edsa","family":"Leal-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alberto","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis","volume":"27","author":"Sonbol MB","year":"2022","unstructured":"Sonbol MB, Mazza GL, Mi L, et al.. Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis. Oncologist. 2022, 27:573-8. 10.1093\/oncolo\/oyac049","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi G","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, et al.. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022, 33:115-54. 10.1007\/s12022-022-09708-2","journal-title":"Endocr Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-024-00535-6","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives","volume":"11","author":"Zhang XB","year":"2024","unstructured":"Zhang XB, Fan YB, Jing R, et al.. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives. Mil Med Res. 2024, 11:35. 10.1186\/s40779-024-00535-6","journal-title":"Mil Med Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-11095-7","article-title":"ESR Essentials: role of PET\/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging","volume":"35","author":"Ebner R","year":"2025","unstructured":"Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. ESR Essentials: role of PET\/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging. Eur Radiol. 2025, 35:1903-12. 10.1007\/s00330-024-11095-7","journal-title":"Eur Radiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari A","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al.. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017, 3:1335-42. 10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020455","article-title":"Everolimus in the treatment of neuroendocrine tumors: lights and Shadows","volume":"13","author":"Medici B","year":"2025","unstructured":"Medici B, Caffari E, Maculan Y, Benatti S, Piacentini F, Dominici M, Gelsomino F. Everolimus in the treatment of neuroendocrine tumors: lights and Shadows. Biomedicines. 2025, 13:10.3390\/biomedicines13020455","journal-title":"Biomedicines"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [(68)Ga]DOTATATE and [(18)F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan DL","year":"2023","unstructured":"Chan DL, Hayes AR, Karfis I, et al.. Dual [(68)Ga]DOTATATE and [(18)F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023, 128:549-55. 10.1038\/s41416-022-02061-5","journal-title":"Br J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.368","article-title":"A rare subset of well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG PET\/CT: is it a sign of an aggressive disease?","volume":"33","author":"Shamseddine A","year":"2022","unstructured":"Shamseddine A, Al Mahmasani L, Elias C, et al.. A rare subset of well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG PET\/CT: is it a sign of an aggressive disease?. Annals of Oncology. 2022, 33:S346. 10.1016\/j.annonc.2022.04.368","journal-title":"Annals of Oncology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-1011","article-title":"The predictive impact of dual somatostatin receptor\/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience","volume":"14","author":"Mohamed A","year":"2023","unstructured":"Mohamed A, Asa SL, Lee Z, et al.. The predictive impact of dual somatostatin receptor\/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience. J Gastrointest Oncol. 2023, 14:1087-94. 10.21037\/jgo-22-1011","journal-title":"J Gastrointest Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a B","year":"2023","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, et al.. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023, 35:e13343. 10.1111\/jne.13343","journal-title":"J Neuroendocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor Control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO Guideline","volume":"41","author":"Del Rivero J","year":"2023","unstructured":"Del Rivero J, Perez K, Kennedy EB, et al.. Systemic therapy for tumor Control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO Guideline. J Clin Oncol. 2023, 41:5049-67. 10.1200\/JCO.23.01529","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz PL","year":"2023","unstructured":"Kunz PL, Graham NT, Catalano PJ, et al.. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023, 41:1359-69. 10.1200\/JCO.22.01013","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao JC","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al.. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011, 364:514-23. 10.1056\/NEJMoa1009290","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000262","article-title":"Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial","volume":"44","author":"Lombard-Bohas C","year":"2015","unstructured":"Lombard-Bohas C, Yao JC, Hobday T, et al.. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015, 44:181-9. 10.1097\/MPA.0000000000000262","journal-title":"Pancreas"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000369780","article-title":"Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors","volume":"60","author":"Wolin EM","year":"2014","unstructured":"Wolin EM. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors. Chemotherapy. 2014, 60:143-50. 10.1159\/000369780","journal-title":"Chemotherapy"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000351103","article-title":"Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report","volume":"59","author":"Nakayama Y","year":"2013","unstructured":"Nakayama Y, Ikeda M, Kojima M, et al.. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report. Chemotherapy. 2013, 59:74-8. 10.1159\/000351103","journal-title":"Chemotherapy"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000448699","article-title":"Efficacy and long-term safety of everolimus in pancreatic neuroendocrine tumor associated with multiple endocrine neoplasia type I: case report","volume":"39","author":"Maia MC","year":"2016","unstructured":"Maia MC, Muniz Louren\u00e7o D Jr, Riechelmann R. Efficacy and long-term safety of everolimus in pancreatic neuroendocrine tumor associated with multiple endocrine neoplasia type I: case report. Oncol Res Treat. 2016, 39:643-5. 10.1159\/000448699","journal-title":"Oncol Res Treat"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33540","article-title":"Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: a pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials","volume":"127","author":"Fazio N","year":"2021","unstructured":"Fazio N, Carnaghi C, Buzzoni R, et al.. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: a pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. Cancer. 2021, 127:2674-82. 10.1002\/cncr.33540","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091332","article-title":"Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management","volume":"11","author":"Altieri B","year":"2019","unstructured":"Altieri B, Di Dato C, Martini C, Sciammarella C, Di Sarno A, Colao A, Faggiano A. Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management. Cancers (Basel). 2019, 11:10.3390\/cancers11091332","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462993-ten-year-disease-control-of-metastatic-pancreatic-neuroendocrine-tumour-treated-with-everolimus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T07:18:48Z","timestamp":1783235928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462993-ten-year-disease-control-of-metastatic-pancreatic-neuroendocrine-tumour-treated-with-everolimus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,5]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.112071","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,5]]}}}